ILD and ANCA: What to do?

Save

Several cohort studies conducted in Asia, Europe and the Americas have evaluated the clinical significance of antineutrophil cytoplasmic antibodies (ANCA) when detected in patients with interstitial lung disease (ILD) as well as the types of ILD encountered in patients with microscopic polyangiitis (MPA) and their effect on the prognosis of MPA.

CAR-T Product Shows Early Promise in Lupus

Save

Five patients with systemic lupus erythematosus (SLE) in China have been treated with a potentially groundbreaking form of chimeric antigen receptor (CAR) T-cell therapy, researchers reported, with encouraging results after 3 months.

High-Resolution CT in CTD-Interstitial Lung Disease

Save

Methylprednisolone plus Methotrexate in Giant Cell Arteritis

Save

Scleroderma-associated Interstitial Lung Disease

Save

While we know there are certain clinical features serving as predictors that patients with SSc may develop ILD, including diffuse skin disease and serologies such as anti-Scl-70 and Th/To antibodies, it is imperative that clinicians consider that any patient, particularly early in their disease course (5 years of disease since the first non-Raynaud phenomenon symptom) could develop ILD. 

Big Fat FDA Pink Slip (9.19.2025)

Save

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip. 

Did Hydroxychloroquine Reduce COVID-19 Mortality?

Save

A multicenter study investigated the association between hydroxychloroquine (HCQ) dosage and COVID-19 mortality among hospitalized patients from multiple medical centers in China. The analysis focused on dose effects of HCQ on mortality.

GLP-1 Drugs Reduce Rheumatoid Arthritis Symptoms

Save

Patients with rheumatoid arthritis (RA) who used GLP-1 receptor agonists had less disease activity and improved cardiovascular biomarkers, a small retrospective study indicated.

What you need to know about scleroderma-related lung fibrosis

Save

What do you need to know about scleroderma-related lung fibrosis as a practicing rheumatologist? Here are takeaways from these guidelines and my practice.

GLP-1 drugs cost-effective for knee osteoarthritis and obesity

Save

A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee osteoarthritis and obesity, with tirzepatide providing greater health benefits at lower cost compared to semaglutide.

SARD-ILD: Significant diagnostic and treatment delays

Save

Should we be screening all our patients with systemic autoimmune rheumatic disease (SARD) for interstitial lung disease? I have been asking myself that question after the recent publication of American Thoracic Society Interstitial Lung Disease screening guidelines. The ATS guidelines, which were published in May, recommend universal CT chest screening for all asymptomatic patients with RA, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren’s disease.

SARD-ILD and serious infection risk: The elephant in the room

Save

Interstitial lung disease (ILD) remains one of the largest unmet clinical needs across many systemic autoimmune rheumatic diseases (SARD). Clinicians are already keenly aware of the complexity of patients with SARD-ILD. The “elephant in the room” for all these issues: serious infection.